Core Viewpoint - Bangshun Pharmaceutical has submitted its main board listing application to the Hong Kong Stock Exchange, with CITIC Securities International as the sole sponsor [1] Company Overview - Established in May 2020, Bangshun Pharmaceutical focuses on the development of innovative oral small molecule drug candidates for oncology and autoimmune diseases [3] - The company has a pipeline that includes one NDA-stage candidate (Bezeixinib), one registration clinical-stage candidate (CX1440), and five preclinical candidates (CX03, CX12, CX13, CX15, and CX16) [3] - Founded by Li Bangliang, former chairman of East China Pharmaceutical, and a core team with extensive industry experience [3] Financial Performance - In 2024, the company reported revenue of 943,000 RMB, with no revenue generated in the first nine months of 2025, marking a 100% decrease compared to the same period in 2024 [4][5] - The net losses for the periods ending in 2024 and the first nine months of 2025 were 88.44 million RMB and 66.34 million RMB, respectively [4][5] - The primary reasons for ongoing losses are attributed to operational expenses, including R&D costs and administrative expenses, as well as changes in the fair value of equity redemption liabilities [5][6] R&D and Market Potential - R&D costs for 2024 and the first nine months of 2025 were 64.53 million RMB and 60.00 million RMB, respectively, driven by accelerated clinical development of core products [6] - The oncology drug market in mainland China is projected to grow from 28.6 billion USD in 2020 to 35.9 billion USD in 2024, with a compound annual growth rate (CAGR) of 5.8%, and is expected to reach 73.4 billion USD by 2030, with a CAGR of 12.6% from 2024 to 2030 [3]
邦顺制药“零收入”冲刺港股，去年前9个月净亏损1.79亿元
Shen Zhen Shang Bao·2026-01-23 07:13